For esophageal cancer, immunotherapy can follow chemoradiation and surgery when cancer remains in the removed tissue, or join drug treatment for unresectable advanced disease. In the U.S., the choice depends on the treatment setting, squamous versus adenocarcinoma histology, PD-L1 testing and prior therapy.[1]
After chemoradiation and surgery
Check the final pathology report for two separate findings: were the surgical margins negative, and was cancer still present in the removed tissue? If both are true after preoperative chemoradiation, the U.S. adjuvant nivolumab indication covers esophageal or gastroesophageal-junction squamous cancer and adenocarcinoma. A positive PD-L1 test is not required. CheckMate 577 randomized 794 such patients, not people whose removed tissue was free of cancer. Median disease-free survival was 22.4 months with nivolumab versus 11.0 months with placebo; this measures time until recurrence or death, not months of overall survival gained. Treatment lasted up to one year or until recurrence or unacceptable side effects.[1][2][3]

Unresectable squamous cancer
For adults starting treatment of unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC), the August 2026 U.S. nivolumab label lists either nivolumab plus fluoropyrimidine–platinum chemotherapy or nivolumab plus ipilimumab when tumors express PD-L1 at the label’s ≥1 threshold.[1]
CheckMate 648 randomized 970 patients and compared each nivolumab combination with cisplatin–fluorouracil chemotherapy, not with each other. Its main analysis used tumor-cell PD-L1 expression. In the FDA label’s separately reported, retrospectively scored CPS ≥1 group, median overall survival was 13.8 versus 9.8 months for nivolumab plus chemotherapy versus chemotherapy, and 12.7 versus 9.8 months for nivolumab plus ipilimumab versus chemotherapy. Exploratory CPS <1 results did not establish benefit in that subgroup.[1][4]
After prior fluoropyrimidine–platinum chemotherapy, the U.S. label separately permits nivolumab alone for unresectable advanced, recurrent or metastatic ESCC without that first-line PD-L1 threshold.[1]
Pembrolizumab for either tumor type
For locally advanced or metastatic esophageal cancer that cannot be treated with surgery or definitive chemoradiation, the U.S. label lists pembrolizumab plus platinum–fluoropyrimidine chemotherapy for squamous cancer or adenocarcinoma when PD-L1 CPS ≥1. It also covers specified junctional tumors centered 1–5 cm above the gastroesophageal junction. In KEYNOTE-590, 647 of 749 enrolled patients had CPS ≥1. In that non-prespecified CPS ≥1 analysis, median overall survival was 12.7 months with pembrolizumab plus cisplatin–fluorouracil versus 9.8 months with chemotherapy alone. This was not a head-to-head comparison with a CheckMate 648 regimen.[5][6]
After at least one prior line of systemic treatment, pembrolizumab alone has a narrower U.S. indication: squamous cancer with CPS ≥10 on an FDA-approved test.[5]
Advanced adenocarcinoma
For advanced or metastatic esophageal adenocarcinoma, the U.S. nivolumab label lists nivolumab with fluoropyrimidine–platinum chemotherapy when tumors express PD-L1 at its ≥1 threshold, not the ESCC-only nivolumab–ipilimumab combination. CheckMate 649 reported CPS ≥1 results from a mixed stomach, junctional and esophageal adenocarcinoma population; only 13% of those patients had an esophageal primary. Known HER2-positive tumors were excluded from the trial. Ask your oncologist whether your tumor’s HER2 result affects how this evidence applies; the pooled survival results are not esophageal-only estimates.[1]
PD-L1 tests
Before applying any ≥1 cutoff, ask whether the pathology report gives a tumor-cell percentage or a combined positive score (CPS). The scores are not interchangeable. CheckMate 648 used the 28-8 assay for tumor-cell PD-L1 grouping, then the U.S. nivolumab label reported a retrospective CPS analysis; CheckMate 649 also reports CPS-based results. The label says there is no FDA-authorized companion diagnostic for the specified advanced esophageal patient-selection uses of nivolumab. That does not mean PD-L1 testing is unavailable. Pembrolizumab’s esophageal label, by contrast, explicitly states CPS thresholds, with an FDA-approved test specified for its later-line single-agent use.[1][5]
Safety
Checkpoint inhibitors can inflame the lungs, bowel, liver or hormone glands. In postoperative CheckMate 577, 794 people were randomized but 792 received treatment. Treatment-emergent events led 68 of 532 nivolumab-treated patients (13%) and 20 of 260 placebo-treated patients (8%) to stop. These are not advanced-combination rates, and “treatment-emergent” does not mean every event was drug-caused. CheckMate 648 excluded people with active autoimmune disease or systemic immunosuppressant use. Report new breathlessness or persistent diarrhea promptly to your oncology team.[2][1]
What to confirm in Japan
Japan’s PMDA/MHLW October 2025 list includes nivolumab for postoperative esophageal cancer and for radically unresectable advanced or recurrent esophageal cancer. It does not by itself establish an individual patient’s Japanese regimen, PD-L1 threshold or access. Take the biopsy, final surgical pathology if applicable, PD-L1 report and treatment history to your oncologist. Ask whether this is the postoperative situation with residual cancer or treatment for unresectable disease, and which regimen is available under current local labeling. U.S. approval does not establish eligibility in Japan.[7]
Editorial disclosure: No article-specific physician review has been documented for this article. This article does not establish that JPNSTEMCELL provides immunotherapy. The site’s medical disclaimer says its health information is not individual medical advice; its administrative role covers authorized record preparation and appointment requests, not cancer-treatment decisions or a promise of immunotherapy access.
Ask about records and appointment coordination
Sources
- [1] U.S. Food and Drug Administration. OPDIVO (nivolumab) prescribing information, revised August 2026; sections 1.13–1.14, 2.1, 5 and 14.13–14.14.
- [2] Horiba MN et al., FDA reviewers. FDA Approval Summary: Nivolumab for the adjuvant treatment of adults with completely resected esophageal/gastroesophageal junction cancer and residual pathologic disease. Clinical Cancer Research, December 15, 2022 (CheckMate 577).
- [3] Kelly RJ et al. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. New England Journal of Medicine, 2021;384:1191–1203 (CheckMate 577).
- [4] Doki Y et al. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. New England Journal of Medicine, 2022;386:449–462 (CheckMate 648).
- [5] U.S. Food and Drug Administration. KEYTRUDA (pembrolizumab) prescribing information, revised February 2026; sections 1.11, 2.1 and 14.11.
- [6] Sun JM et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590). The Lancet, 2021;398:759–771.
- [7] Japan Pharmaceuticals and Medical Devices Agency / Ministry of Health, Labour and Welfare. Pharmaceuticals and Medical Devices Safety Information No. 423, October 2025, nivolumab indications (p. 18); English translation, Japanese original controls.